Opus Genetics (IRD) Return on Sales (2010 - 2026)

Opus Genetics (IRD) has 9 years of Return on Sales data on file, last reported at 0.3% in Q1 2026.

• On a quarterly basis, Return on Sales fell 29.0% year-over-year to 0.3% in Q1 2026; TTM through Mar 2026 was 0.08%, a 4.0% decrease from a year earlier, with the FY2025 full-year figure at 0.03%, up 2.0% from the prior year.
• Return on Sales for Q1 2026 stood at 0.3%, down from 0.02% in the prior quarter.
• Over the last five years, Return on Sales for IRD reached as high as 0.01% in Q4 2022 and fell as low as 0.45% in Q2 2022.
• Historically, Return on Sales has averaged 0.1% across 5 years, with a median of 0.03% in 2023.
• Across the five-year window, Return on Sales surged 97 bps in 2022 and slipped 29 bps in 2026, its largest moves.
• Year by year, Return on Sales stood at 0.01% in 2022, then sank by 433 bps to 0.03% in 2023, then plunged by 188 bps to 0.08% in 2024, then jumped by 81 bps to 0.02% in 2025, then slumped by 1822 bps to 0.3% in 2026.
• Per Business Quant data, the three most recent Return on Sales figures were 0.3% in Q1 2026, 0.02% in Q4 2025, and 0.06% in Q3 2025.